# Astrana Health Inc. (ASTH) Stock Analysis: A Healthcare Contender with a 92% Potential Upside

- Link: https://www.directorstalkinterviews.com/astrana-health-inc-asth-stock-analysis-a-healthcare-contender-with-a-92-potential-upside/4121205429
- Published: 2025-07-01T10:46:13+01:00
- Author: Madison Wilson

Astrana Health Inc. (ASTH), a prominent player in the healthcare sector, has been
attracting significant attention from investors due to its substantial growth potential
and strategic positioning within the medical care facilities industry. With a market
capitalization of $1.15 billion, this Alhambra, California-based company is poised
for expansion as it navigates the complexities of the U.S. healthcare system.

Currently trading at $24.88, Astrana Health has experienced a modest price change
of 0.15 (0.01%), reflecting a period of relative stability. However, the stock’s
52-week range, from $24.00 to $62.54, indicates a history of significant volatility.
This fluctuation presents both a challenge and an opportunity for investors looking
to capitalize on its growth trajectory.

A key metric capturing investor interest is Astrana Health’s forward P/E ratio of
11.01, suggesting a potentially undervalued stock given its robust revenue growth
of 53.40%. Despite not reporting net income, the company boasts an EPS of 0.73 and
a commendable return on equity of 8.10%. Nevertheless, its free cash flow is currently
negative at -$49.4 million, which may raise concerns regarding liquidity and financial
health.

Astrana Health’s analyst ratings further underscore its investment appeal. With 
eight buy ratings, three hold ratings, and zero sell ratings, the consensus leans
strongly toward a bullish outlook. Analysts have set a target price range of $36.00
to $70.00, with an average target of $47.89, indicating a potential upside of 92.48%
from its current price. This significant upside potential makes Astrana Health a
noteworthy consideration for investors seeking growth opportunities in the healthcare
sector.

Dividend-seeking investors may find Astrana Health less appealing, as the company
does not currently offer a dividend yield, maintaining a payout ratio of 0.00%. 
This decision aligns with its growth-focused strategy, channeling resources toward
expansion and operational improvements rather than immediate shareholder returns.

From a technical perspective, Astrana Health’s 50-day moving average stands at 27.35,
while the 200-day moving average is notably higher at 37.81. The Relative Strength
Index (RSI) of 78.38 suggests the stock is currently in overbought territory, which
could imply a potential price correction in the short term. Additionally, the MACD
of -0.58 and signal line of -0.71 indicate a bearish trend, warranting cautious 
consideration for timing entry points.

As a healthcare management company, Astrana Health’s operations span care coordination
services across various segments, including Care Partners, Care Delivery, and Care
Enablement. Its extensive physician network serves a diverse patient base covered
by private and public insurance programs, such as Medicare and Medicaid, as well
as non-insured individuals.

Founded in 1994 and rebranded as Astrana Health, Inc. in February 2024, the company
continues to evolve, aiming to enhance its service offerings and expand its market
reach. For investors with a focus on the healthcare sector, Astrana Health presents
a compelling case for potential growth, albeit with some financial and market volatility
risks to consider. As always, thorough due diligence and an understanding of personal
investment goals are essential when evaluating this promising healthcare stock.

Share on: